Structured Review

Horizon Discovery i fect encapsulated non targeting dsrna
A. Experimental design. (Ith: Intrathecal; siRNA: Raf-1 siRNA or mismatch siRNA delivery via intrathecal catheter; BL: Baseline; D: Day; IR: Infrared heat). B. Raf-1 siRNA attenuates sustained morphine-mediated thermal hyperalgesia in rats: Male Sprague Dawley rats received intrathecal injections of <t>i-Fect</t> encapsulated Raf-1selective siRNA (Raf-1 siRNA groups); or non-targeting <t>dsRNA</t> (mismatch siRNA groups) or the transfection agent (i-Fect) alone (control) once daily, for 3 days. After pre-treatment, the rats received continous subcutaneous (osmotic minipump) saline (control group, Raf-1 siRNA group and mismatch siRNA group) or morphine (45μg/μl/h) (morphine group, Raf-1 siRNA+morphine group and mismatch siRNA+morphine group) infusions for 6 days. Six animals were included in each treatment group. Thermal hyperalgesia was measured as a decrease in paw withdrawal latencies in a radiant heat paw-withdrawal test.
I Fect Encapsulated Non Targeting Dsrna, supplied by Horizon Discovery, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/i fect encapsulated non targeting dsrna/product/Horizon Discovery
Average 85 stars, based on 1 article reviews
Price from $9.99 to $1999.99
i fect encapsulated non targeting dsrna - by Bioz Stars, 2020-07
85/100 stars

Images

1) Product Images from "Intrathecal Raf-1-selective siRNA attenuates sustained morphinemediated thermal hyperalgesia"

Article Title: Intrathecal Raf-1-selective siRNA attenuates sustained morphinemediated thermal hyperalgesia

Journal: European journal of pharmacology

doi: 10.1016/j.ejphar.2008.10.033

A. Experimental design. (Ith: Intrathecal; siRNA: Raf-1 siRNA or mismatch siRNA delivery via intrathecal catheter; BL: Baseline; D: Day; IR: Infrared heat). B. Raf-1 siRNA attenuates sustained morphine-mediated thermal hyperalgesia in rats: Male Sprague Dawley rats received intrathecal injections of i-Fect encapsulated Raf-1selective siRNA (Raf-1 siRNA groups); or non-targeting dsRNA (mismatch siRNA groups) or the transfection agent (i-Fect) alone (control) once daily, for 3 days. After pre-treatment, the rats received continous subcutaneous (osmotic minipump) saline (control group, Raf-1 siRNA group and mismatch siRNA group) or morphine (45μg/μl/h) (morphine group, Raf-1 siRNA+morphine group and mismatch siRNA+morphine group) infusions for 6 days. Six animals were included in each treatment group. Thermal hyperalgesia was measured as a decrease in paw withdrawal latencies in a radiant heat paw-withdrawal test.
Figure Legend Snippet: A. Experimental design. (Ith: Intrathecal; siRNA: Raf-1 siRNA or mismatch siRNA delivery via intrathecal catheter; BL: Baseline; D: Day; IR: Infrared heat). B. Raf-1 siRNA attenuates sustained morphine-mediated thermal hyperalgesia in rats: Male Sprague Dawley rats received intrathecal injections of i-Fect encapsulated Raf-1selective siRNA (Raf-1 siRNA groups); or non-targeting dsRNA (mismatch siRNA groups) or the transfection agent (i-Fect) alone (control) once daily, for 3 days. After pre-treatment, the rats received continous subcutaneous (osmotic minipump) saline (control group, Raf-1 siRNA group and mismatch siRNA group) or morphine (45μg/μl/h) (morphine group, Raf-1 siRNA+morphine group and mismatch siRNA+morphine group) infusions for 6 days. Six animals were included in each treatment group. Thermal hyperalgesia was measured as a decrease in paw withdrawal latencies in a radiant heat paw-withdrawal test.

Techniques Used: Transfection

Related Articles

Transfection:

Article Title: Intrathecal Raf-1-selective siRNA attenuates sustained morphinemediated thermal hyperalgesia
Article Snippet: .. After recovery from the surgery (5–7 days), the animals received intrathecal injections (2ug siRNA/10 ul/rat) of either a lipid encapsulated Raf-1-selective siRNA mixture (Smart pool siRNA, Dharmacon Inc; Chicago, IL, Cat # L-087699-00 ) (Raf-1 siRNA groups) or i-Fect encapsulated non-targeting dsRNA (Dharmacon, # D-001810-01-20 ) (control mismatch siRNA groups) or the transfection lipid alone, once daily, for 3 days, as described earlier ( ). .. Intrathecal injections of the siRNAs or the transfection agent alone did not cause any sign of behavioral toxicity.